Bioidentical Hormones - U.S. Senate Special Committee on Aging

21.Grodsteln F. Manson JE, Colditz GA, Witlen WC, Spelzer FE,
Stampfer NU. A prospective, observational study of postmenopausal
hormone therapy and primary prevention of
cardiovascular disease. AnnIntemMed2000,133:933-4I.
22.Fatkebom M, Persson 1, Adaml HO et aL The risk of acute
myocardtal Infarction aUter estrogen and estrogen-progestogen
replacement Birtr Obstet G)"ecol t992,90.821-8.
23.Psaty BM, Hectbert SRP Aticdos D er zL The risk of myocardial
Infarction associated with the combined use of estrogens and
progestins in postnenopausal women. Arch Inten Med
1994;l54:1333-9.
24.Wlson PW, Garrison RJP Casteeil WP. Postmenopausal estrogen
use, cigarette smoking, and cardiovascular moobidty In women
over 50. The framingham study. N Engi J Med 1985;
313:1038-43.
25.Roisouw JE. Debate: the potential role of estrogen In the
preventIon of heant disease in women after menopause. Cunr
Control 771ts Cardvasc Med2000;:1A35-8.
26Sotelo MM, Johnson SR. The effects of hormone replacement
therapy on coronary heart disease. Endoinotl Meaab Cl/n
North Am 1997;26:313-28.
27.Grodsteln F, Stamapter Ml, Manson IE et al Postanenopausa
estrogen and progestin use and the risk of cardiovascular dis,
ease. NEngl/Med 1996,335:453-61.
28.Criqul MH, Suarez I, Barrent-Connor E, McPhillips I,
Wingard DL, Garland C. Postnenopausal estrogen use and mortality.
Results from a prospective study In a defined, homo
geneous cotcmuntty. AmJEptdemt/ 1988;128:606-14.
29.Herandez Avila M, Walker AM, lick H. Use of replacement
estrogesns and the risk of myocardisi Infarction. Epkk fokV
19901:128-33.
30SIdney 5, Pelitti DB, Ouesenberry CP Jr Myocardisi Inatrction
and the use of estrogen and estrogenproggstogen in postmenopausal
women. Ann Intem Med 1997;127:501-8.
3I.Rosenberg I, Slone D, Shapiro S, Kaufman D, Stottey PD,
Miettinen OS. Noncontraceptive estrogens and myocardial
Infarction In young women. 14MW 1980,244:339-42.
32.Heckbert SR Weiss NS, Koepse TID et lL Duration of estrugen
replacement therapy in relation to the rink of incident myocardial
htfarction in postoenopausal women. Arch Intem Med
1997;157:1330-6.
33.Hemmintd E, McPherson K. Impact of postnenopausal hormone
therapy on cardiovascular events and cancer: pooled data
from clitical traLL 8Mtt997;315:149-53.
3
4.Women's Health Initiative Study Group. Design of the
Women's Health InItiatIve clinical trat and observatonal study.
Crn0rol Cltn 11dls 1998l19-61-109.
35 hrl.//ww .nhdtibnlhpgv/wlsihrLhtm
36.Vlckers MR, Meade TW, Wlikes HC. Hormone replacement
therapy and cardiovascular disease: the case for a randomized
conrotiled trial. Clba FoundSymnp 1995;19:150-60.
37.COKeefe JH Jr, Kim SC, Hall RR, Cochran VC, Lawhorn SL,
McCalgister BD. Estrogen replacement therapy after coronary
angioplasty in women. JAm Coel Cardio 1997;291-5.
383Abu-Halawa SA, Thompson K, Kirkeelde R. et dL Estrogen
replacemnent therapy and outcome of coronary balten angloplasty
in posnmenopausal women. Am J Cantalo 1998j82:
409-13.
194
Postmenopausal hormone therapy and cardiovascular disease
39.Satiivan JM, Et-Zeky F, Vander Zwaag R, Ramanathan KB Effect
on survival of estrogen replacement therapy after coronary
artery bypass grafting AmJ CIr/Yol 1997;79'.847-50.
405hcteftbrd DP, Daniels S, Hoffman MK, Chitwood R. Estrogen
therapy In women undergoing comnaly artety bypass gradl
effect on surgical complicataons bet CQvneco 2000;9S:
732-S.
41Shlpak MG, Angela BG, Go AS, Frederick PD, Canto JG.
Grady D. Hormone therapy and In-hospital survival after
myocardtal infarction In postuenopausat women. Cmirulaf/on
2001; 104:2300-4.
42.Grodsteln F, Manson IE, Stanspfer MJ. Postmenopausarl hormone
use and secondary prevention of comnary events in the
nurses' health study a prospective, observational study. Ann
InternMed200I;135:I-8.
43,Alexander KP, Newby LK, Hellkamp AS et ai Initiation of hormone
replacement therapy after acute myocardial hfarction Is
associated with more cardiac events during fotlow-up. J Am
Coi Cardbf200L,31:l-7.
44.Heckbert SR, Kaplan RC, Weiss NS ed a Risk of recurrent coronary
events in relation to use and recent intitiation of post
menopausal hormone therapy. Arch Intem Med 2001;1611
1709-13.
45.Huttey S, Grady D, Bush T et al Randomized trial of estrogen
plus progmestn for secondary prevention of coronary heart disease
In postmenopausol women. 1AMA 1998,280:605-13.
46.Herrington DM, Reboussin DM, Brosntihan. KB et at Effects of
estrogen repiacement on the progesston ofcoronary-artery atherosclerosis.
N&W1Med2O00O343:522-4.
47.Schulman SP, Thiemano DR, Ouyang P et al Effects of acute
hormone therapy on recurrent ischemla in postmenopausal
women with mutable angna. J Am Coa Card/at 2002i39:
231-7.
48.Mendelsohn ME, Karas RH. The time has come to stop letting
the HERS tale wag the dogma. Chculation 2001; 104: 2256-9.
49Rosano GM, FRo M. Postnenopausal women and carddovascular
risin impact of hormone replacement therapy. Card/of Rev
2002;10t51-O.
S0.osano GM, Simon T, Mercuro G et al Hormone replacement
therapy'. where we stand in Europe. Eur Heart 1 2001;
22.439-41.
5 l.Wenger Nt, Knatterud CL, Canner PL Early risks of hormone
therapy in patients with coronary heart disease. JAM4
2000',284:41-3.
52.Clatze S, Kelleher 1, Lloyd-Janes H, Sharples I, Slack M,
Schofteld PM. Transdermal hormone replacement therapy
for the secondary prevention of coronary artery disease
in postmenopausal women (abstrac). Eur Heart I 2000;
21212.
53.Viscofi CM, Brass LK, Keroan WN, Sarrel PM, Sulssa S,
Horwimz RL A clinical traia of estrogen-replacement therapy
after ischeicsndtmke. NEngfJMed200l;345:1243-9.
54.htaan MA, Heagerty AM, Kitchener H, McNamee R,
Cherry NM, Hannaford P. Oestrogen and women's heart
diseasetr ESPRIT-UL 01Med2000,93:t99-702.
55.Barrets-Connor E, Grady D, Sasheqjy A et at MORE
bnvestigatro Ralatoxne and cardiovarular events In osteporotic
posnwatopousal wonten. IAMA 2002M27:847-57.